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Abstract
Cardiovascular diseases (CVD) are the leading cause of death worldwide. Individual
detection and intervention on CVD risk factors and behaviors throughout childhood
and adolescence has been advocated as a strategy to reduce CVD risk in adulthood.
The U.S. National Heart, Lung, and Blood Institute (NHLBI) has recently recommended
universal screening of several risk factors in children and adolescents, at odds with
several recommendations of the U.S. Services Task Force and of the U.K. National
Screening committee. In the current review, we discuss the goals of screening
for CVD risk factors (elevated blood pressure, abnormal blood lipids, diabetes)
and behaviors (smoking) in children and appraise critically various screening
recommendations. Our review suggests that there is no compelling evidence to
recommend universal screening for elevated blood pressure, abnormal blood
lipids, abnormal blood glucose, or smoking in children and adolescents. Targeted
screening of these risk factors could be useful but specific screening strategies
have to be evaluated. Research is needed to identify target populations, screening
frequency, intervention, and follow-up. Meanwhile, efforts should rather focus on the
primordial prevention of CVD risk factors and at maintaining a lifelong ideal
cardiovascular health through environmental, policy, and educational approaches.
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Introduction
Cardiovascular diseases (CVD) are the leading cause of death worldwide with a burden
of over 17 million deaths per year (31 % of the global total) [1]. They are frequent in
elderly but occur rarely before the age of 60 years. Nevertheless, the pathogenic
process of atherosclerosis causing CVD begins early in life, in particular during child-
hood and adolescence [2, 3]. CVD risk factors and risk behaviors can be detected in
childhood, and the extent of their presence has been linked to the severity of athero-
sclerosis in childhood and in adulthood [2–6]. There is also growing evidence that
CVD risk factors and behaviors track to various degrees into adulthood, contributing
to the risk of diseases decades later [7–11]. Therefore, individual detection and inter-
vention on CVD risk factors and behaviors throughout childhood and adolescence has
been advocated as a strategy to reduce CVD risk in adulthood [5, 6, 12].
Hence, in a viewpoint published in 2009, McGill et al. argued that “[…] pediatricians
[should be] responsible for the prevention of adult cardiovascular diseases” [6]. Indeed,
as the development of CVD begins early in life and CVD risk factors are identifiable in
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children, he argued that individualized clinical prevention of CVD beginning in child-
hood should be considered. Recent recommendations of the U.S. National Heart, Lung,
and Blood Institute (NHLBI) for the universal screening of several risk factors are
coherent with this approach and have raised a debate about the role of CVD risk
factors screening during childhood [13].
In the current review, we discuss the goals of screening for several CVD risk factors (elevated
blood pressure, abnormal blood lipids, diabetes) and behaviors (smoking) in children and
adolescents (below 19 years of age) and appraise critically various screening recommendations.
Review
Goals and peculiarities of screening for CVD risk factors in children and adolescents
Possible strategies for CVD prevention starting in childhood are either to prevent the
development of risk factors in the first place (primordial prevention) [12] or to identify
and treat children with major risk factors predisposing them to develop clinical disease
several decades later (primary prevention) [5, 6]. For the later strategy, the identifica-
tion of children is possible through screening. The aim of any screening activity is to
identify in a healthy population the individuals who are at increased risk for a disease
or who have the disease at an early stage [14, 15]. Once screened, these individuals are
offered further testing to confirm or not the presence of the disease and, if necessary,
have early intervention either to cure the disease or to prevent major consequences of
the disease [15]. In CVD prevention starting in childhood, screening aims therefore to
detect children carrying risk factors or risk behaviors for CVD, in order to intervene
early and reduce their risk to develop clinical manifest diseases later in life.
Following the classical Wilson-Jungner criteria to assess whether any condition po-
tentially warrants screening efforts, several conditions have to be fulfilled before recom-
mending screening for CVD risk factors in children (Table 1) [16, 17]. A first criteria is
that the prevalence of the screened condition should be known. While prevalence of
smoking in children and adolescents is relatively well documented in many populations
[18], much less is known on the prevalence of elevated blood pressure [19–21] and dys-
lipidemia [22], and the situation is even worst for diabetes [23–25]. Second, the natural
history linking risk factors to CVD and the absolute risk of CVD associated with a
given level of risk factors should be documented. While this risk is well documented in
adults, only indirect evidence exists in children, i.e., through cohort studies having
shown the association between CVD risk factors in childhood and surrogate marker of
CVD in young adulthood [2–6, 26, 27]. Third, a valid and reliable screening test should
Table 1 Issues to consider when assessing the relevance of screening for cardiovascular
disease (CVD) risk factors in children and adolescents. Adapted from the Wilson-Jungner criteria [17]
1. The condition should be a major and modifiable risk factor for CVD with a known prevalence in the
population
2. The absolute risk of CVD associated with a given level of risk factor should be known
3. There should be a valid, reliable, and acceptable screening test to identify the risk factor in children
and adolescent
4. The best screening strategy should be known (e.g., universal versus targeted screening)
5. There should be an agreement on whom to treat; further, the benefits harms, and costs of treatment
should be known (treatment early in life should be associated with a better outcome than treatment later in
life, accounting for lead time bias)
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exist, different screening strategies should have been evaluated, and reference values
(for blood pressure, lipids, and glucose) should be available [20, 22, 28]. Finally, there
should be an agreement on whom to treat and the benefits, harms, and costs of treat-
ment should be documented. As screening engages healthy children and adolescents
and since the treatment may be necessary for many decades, the balance of benefits
and harms is of particular concern. Avoidance of overdiagnosis and overtreatment is of
major importance in the evaluation of screening strategies [29].
Recommendations for the screening for CVD risk factors in children and adolescents
In the integrated guidelines for the cardiovascular health, experts from the NHLBI rec-
ommend the screening of several CVD risk factors at various ages during childhood
(Table 2) [13]. However, most of these recommendations are at odds with the recom-
mendations of the U.S. Preventive Services Task Force (USPSTF) [30] and of the U.K.
National Screening Committee [31].
Screening for elevated blood pressure
Hypertension is a major risk factor for CVD in adults [32]. As there is growing
evidence that sustained elevated blood pressure in childhood causes persistent
Table 2 Screening of cardiovascular diseases (CVD) risk factors in children and adolescents
recommended by the the U.S. National Heart, Lung, and Blood Institute (NHLBI) [13], by the U.S.
Preventive Services Task Force (USPSTF) [30], and by the U.K. National Screening committee [31]
Screening NHLBI recommendations USPSTF recommendations U.K. National Screening
committee
Elevated blood
pressure
Annual blood pressure
measurement in all children
from age 3 year; targeted
measurement in infants
with renal/urologic/cardiac
diagnosis or history of
neonatal intensive care
before the age of 3 year
Evidence insufficient to assess
the balance of benefits and
harms of screening for primary
hypertension in asymptomatic
children and adolescents
to prevent subsequent
cardiovascular disease in
childhood or adulthood.
Systematic population
screening not
recommended
Dyslipidemia/abnormal
blood lipids
Universal lipid screening at
age 9–11 year; measurement
of non-fasting or fasting lipid
profile; targeted screening
according to family history
or other high risk condition
before the age of 9–11 year
Evidence insufficient to
recommend for or against
routine screening for lipid
disorders in infants, children,
adolescents, or young adults
(up to age 20).
Systematic population
screening not
recommended
Diabetes Targeted screening at age
9–11 year following the
American Diabetes
Association guidelines,
i.e., in overweight children
and with two or more
additional risk factors for
diabetes [ADA 2014]
No specific recommendation
for children or adolescents
No specific
recommendation for
children or adolescents
Smoking Assessment of tobacco use
beginning at 9–11 year
Recommendation that primary
care clinicians provide
interventions, including
education or brief counseling,
to prevent initiation of tobacco
use among school-aged
children and adolescents. No
recommendation to screen
for tobacco use.
No specific
recommendation for
children or adolescents
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cardiovascular alterations and tracks into adulthood, several guidelines recom-
mended universal screening for hypertension in childhood starting at the age of
three [13, 33, 34]. However, recent, exhaustive reviews have concluded that the evidence
to recommend universal hypertension screening in childhood was limited [21, 35, 36].
While it seems reasonable to assume that children with hypertension are at increased
risk for CVD in adult life, no study has lasted long enough to link directly elevated
blood pressure in childhood to the risk of CVD in adulthood. The absolute risk of
CVD associated with a given pediatric blood pressure level is, indeed, unknown
[20, 21]. As a consequence, a BP threshold above which intervention is beneficial
is not known in children. Further, although lifestyle or pharmacologic interventions
for hypertension in childhood have been shown to decrease blood pressure in the
short-term, the long-term benefits and harm are unknown [20]. It is therefore un-
known whether potential harms outweigh the expected benefices.
Due to the length of the pathogenic process and since CVD occurs rarely before the
age of 60, one can assume that no randomized controlled trial to assess the direct effect
of any BP reduction intervention in childhood on the absolute risk of CVD will be ever
conducted. In a cost-effective simulation study, neither universal screening with treat-
ment of those with hypertension or treatment of those with end-organ injury, nor
targeted screening in overweight adolescents was shown to perform better than
population-based interventions [37].
A further major issue is that CVD risk factors like blood pressure or blood lipids are
relatively weak CVD predictors (Fig. 1) [14, 38]. Indeed, the discriminative power of
blood pressure or blood lipids for having or not a CVD later in life is weak. For
instance, while individuals with elevated blood pressure have a higher risk of CVD,
many cases of CVD will occur in individuals with normal blood pressure. This is why
high risk prevention strategies based notably on screening are not sufficient to prevent
CVD in the population, what requires population-based prevention strategies to have a
favorable effect on the distribution of risk factors in the whole population [39, 40].
Fig. 1 Blood pressure would be an ideal risk marker for screening if the distribution of blood pressure in
individuals having a cardiovascular disease (CVD) was very different than in individuals not having a CVD (a).
However, blood pressure is a relatively weak risk factor for CVD (i.e., elevated blood pressure is a poor
discriminator for sorting out individuals who will have a CVD form other individuals) as there is no
large difference in the distribution of blood pressure between individuals having CVD and individuals
not having a CVD (b) [14, 38]. The same is true for blood lipids
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Screening for dyslipidemia
In adults, high levels of total cholesterol and low density lipoprotein-cholesterol
(LDL-C) are important risk factors for coronary heart disease. Further, there is also
good evidence that lipid-lowering treatment substantially decreases the incidence of
coronary heart disease in persons with dyslipidemia [41]. Therefore, the USPSTF
strongly recommends blood lipids screening in men aged 35 and women aged 45
[42]. It is also well known that the effect of lipid-lowering treatment will depend
on the absolute risk of CVD. As age is the main determinant of CVD risk, the
USPSTF does not recommend screening before the age of 35 in men and 45 in
women as below that age, the absolute risk of CVD is low and the benefit of treat-
ment is expected to be minimal. In younger adults, the USPSTF recommends tar-
geted screening only in high risk individuals, i.e., having a family history of CVD
at a young age, smokers, or a personal history of diabetes or hypertension [42].
In children, the USPSTF argue that evidence is insufficient to recommend for or
against routine screening for lipid disorders in infants, children, adolescents, or young
adults (up to age 20) [43] (an update of this recommendation is ongoing). The UK
National Screening committee does not recommend screening in children. At odds
with this recommendation, the NHLBI recommended in 2012 universal screening for
dyslipidemia in children aged 9–11 years old and targeted screening in high risk
children at younger age [13]. These recommendations have raised an important de-
bate, with strong doubts about their efficiency and concerns about their potential
harms [44–47].
Following the NHLBI guidelines, the primary goal of universal screening is identifying
cases of familial hypercholesterolemia (FH) [46]. FH is indeed the most prevalent pri-
mary dyslipidemia in children, reaching 1 in 250–500 of individuals [48]. It is a severe
form of dyslipidemia associated with a very high risk of CVD; the cumulative risk for
coronary heart disease is estimated to be greater than 50 % in men by the age of 50
and 30 % in women by the age of 60 [49]. Statin treatment in these children is efficient
(with beneficial effect shown on surrogates markers of CVD) and safe [46]. However,
while lifetime treatment is potentially required, long term safety is not established.
Targeted screening to high risk children (e.g., with obesity or a family history of CVD
at an early age) and cascade screening (i.e., systematic screening of close relatives of
previously diagnosed index cases) has been proposed as alternative to universal screen-
ing for the detection of FH [48, 49]. For instance, the UK National Institute for Health
and Clinical Excellence recommends cascade screening using a combination of genetic
testing and LDL cholesterol concentration measurement of close (first-, second-, and
third-degree) biological relatives of people with FH [49]. Pediatricians favor targeted
screening as shown by the higher proportion of test for blood lipids among children
with obesity in the United States [50].
Screening for diabetes
Hyperglycemia accelerates atherosclerosis and is a cause of CVD [51, 52]. Screening for
abnormal blood glucose (impaired fasting glucose or impaired glucose tolerance) and
type 2 (T2DM) diabetes mellitus is recommended by the USPSTF in adults at high risk
of diabetes [53]. The goal of screening in adults is to prevent progression of abnormal
blood glucose to T2DM and long term complications of diabetes, either microvascular
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(retinopathy, neuropathy, nephropathy) or macrovascular (i.e., CVD) complications.
Early treatment of T2DM in adults has been shown to be associated with a lower rate
of microvascular complications.
In children, type 1 (T1DM) diabetes mellitus is much more frequent than T2DM
[23–25]. T1DM is a different condition than T2DM and characterized by a lack of insu-
lin secretion by the pancreas. T1DM develops rapidly, sometimes with dramatic conse-
quences, and there is no true preclinical indicator that could be easily targeted for
screening. Due to the increasing prevalence of obesity, abnormal blood glucose and
T2DM is expected to be increasingly frequent in children and adolescents [25, 54].
Elevated blood glucose in childhood is a predictor of prediabetes and T2DM in
adulthood [54].
While there is no specific recommendation by the USPSTF or by the UK National
Screening committee for the screening of abnormal blood glucose and T2DM, several
guidelines recommend targeted screening for glucose intolerance in children at high
risk, e.g., due to the presence of overweight or other risk factors (ethnicity, family his-
tory of T2DM, signs of insulin resistance or conditions associated with, maternal gesta-
tional diabetes) [13, 55]. No guidelines recommend universal screening in children and
adolescents.
Screening for smoking
Smoking is highly addictive and a major risk factor for CVD [56]. Worldwide, it kills
over 5 million persons per year [56]. Helping smoking cessation is efficient in adults
and the USPSTF recommends that clinicians ask all adults about tobacco use and pro-
vide tobacco cessation interventions for those who use tobacco products [57]. As most
adult smokers started to smoke during late childhood and adolescence [58], interven-
tions to prevent initiation or help cessation of smoking during childhood and adoles-
cence are warranted. Cochrane reviews have shown that school- and family-based
interventions can help prevent smoking initiation in children and adolescents [59, 60].
Evidence on the effect of interventions for smoking cessation in adolescents is less
convincing [58, 61, 62]. The American Medical Association’s (AMA) Guidelines for
Adolescent Preventive Services (GAPS) recommend that “all adolescents should be
asked annually about their use of tobacco products including cigarettes and smokeless
tobacco” [61]. However, a recent systematic review assessing evidence for the efficacy
and harms of primary-care interventions to reduce tobaccos use in children and adoles-
cents has shown that smoking initiation could be prevented by behavior based inter-
ventions but that neither behavior-based nor pharmacologic interventions improved
cessation rate [62]. Based on this review, the USPSTF recommends that primary care
clinicians provide interventions, including education or brief counseling, to prevent ini-
tiation of tobacco use among school-aged children and adolescents [63]. The USPSTF
does not recommend screening for smoking.
Conclusion
Since 50 years, the prevention of CVD is a success story among adults of high-income
countries. Indeed, CVD mortality rates have sharply decreased, e.g., in the United-
States, Canada or Switzerland, in both sexes and in all age strata of the population [64].
Population-based as well as high-risk prevention strategies have contributed to this
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large decrease in CVD [65]. It is increasingly accepted that CVD prevention strategies
should include children as well as adults [66]. Nevertheless, even if the pathogenic
process of CVD originates in childhood, it does not imply that the model of adult CVD
clinical prevention strategies is applicable to children. Our review suggests indeed that
there is no compelling evidence to recommend universal screening for elevated blood
pressure, abnormal blood lipids, abnormal blood glucose, or smoking in children and
adolescents. Targeted screening of these risk factors could be useful but specific screen-
ing strategies have to be evaluated [44, 45, 67].
Research is needed to identify target populations, screening frequency, intervention
and follow-up. Further, research is needed to assess the effect of early life screening
and treatment of CVD risk factors. Since CVD are remote outcomes, rarely occurring
before the age of 60 years, the effect of early life screening and treatment should be
tested in trials using more proximal outcomes, i.e., proxies such as carotid intima-
media thickness which have been shown to be associated with CVD risk factors in
childhood and adolescence. Meanwhile, efforts should rather focus on the primordial
prevention of CVD risk factors [12] and at maintaining a lifelong ideal cardiovascular
health through environmental, policy, and educational approaches [68].
Abbreviation
CVD: Cardiovascular diseases; BP: Blood pressure; USPSTF: U.S. Preventive Services Task Force; NHLBI: U.S. National Heart
Lung, and Blood Institute.
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